This week, the ratings of 15 Pharmaceuticals stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

This week, Perrigo Co. Plc’s (PRGO) rating worsens to a D from the company’s C rating a week ago. Perrigo Co. Plc manufactures, distributes and markets pharmaceutical and nutritional products. The company also gets F’s in operating margin growth and earnings growth. For more information, get Portfolio Grader’s complete analysis of PRGO stock.

Jazz Pharmaceuticals Plc’s (JAZZ) rating weakens this week, dropping to a D versus last week’s C. Jazz Pharmaceuticals Plc is a specialty pharmaceutical company focused on developing and commercializing products to meet medical needs in neurology and psychiatry. The company also gets F’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of JAZZ stock.

Valeant Pharmaceuticals International, Inc. (VRX) slips from a D to a F this week. Valeant Pharmaceuticals International, Inc. develops and distributes drugs. The company also gets F’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of VRX stock.

Slipping from a C to a D rating, Zoetis, Inc. Class A (ZTS) takes a hit this week. For more information, get Portfolio Grader’s complete analysis of ZTS stock.

This week, Sanofi Sponsored ADR (SNY) drops from a C to a D rating. Sanofi Sponsored ADR is a global pharmaceutical company that researches, develops and manufactures prescription pharmaceuticals and vaccines. For more information, get Portfolio Grader’s complete analysis of SNY stock.

Pfizer Inc. (PFE) experiences a ratings drop this week, going from last week’s C to a D. Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The company also gets F’s in earnings growth. For more information, get Portfolio Grader’s complete analysis of PFE stock.

Phibro Animal Health Corporation Class A (PAHC) earns a D this week, moving down from last week’s grade of C. The company also gets F’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of PAHC stock.

Relypsa, Inc. (RLYP) is having a tough week. The company’s rating falls from a D to a F. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of RLYP stock.

Sagent Pharmaceuticals, Inc. (SGNT) declines this week from a D to a F. Sagent Pharmaceuticals, Inc. is an injectable pharmaceutical company. The company also gets F’s in earnings growth, earnings revisions, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of SGNT stock.

This is a rough week for Amphastar Pharmaceuticals Inc (AMPH). The company’s rating falls to D from the previous week’s C. The company also gets F’s in earnings surprise. For more information, get Portfolio Grader’s complete analysis of AMPH stock.

Flex Pharma, Inc. (FLKS) gets weaker ratings this week as last week’s D drops to a F. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of FLKS stock.

Slipping from a C to a D rating, Agile Therapeutics, Inc. (AGRX) takes a hit this week. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of AGRX stock.

This is a rough week for Cipher Pharmaceuticals Inc. (CPHR). The company’s rating falls to F from the previous week’s D. The company also gets F’s in operating margin growth, earnings growth, earnings revisions, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of CPHR stock.

Evoke Pharma, Inc. (EVOK) declines this week from a C to a D. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of EVOK stock.

Alimera Sciences, Inc. (ALIM) is having a tough week. The company’s rating falls from a D to a F. Alimera Sciences, Inc. engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company also gets F’s in earnings revisions and free cash flow. For more information, get Portfolio Grader’s complete analysis of ALIM stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.